Disease Clusters?

Groups of diseases that share a large number of curated genes with each other, computed via label propagation over the shared-gene similarity graph. See also Shared-Gene Disease Pairs for pairwise comparisons.

← Back to all clusters

Cluster 9

30 diseases · 98 shared-gene connections
30 Diseases
486 Unique genes
0.273 Avg. similarity score
Therapy related acute myeloid leukemia and myelodysplastic syndrome Most-connected disease (20 links)
Log in to save this analysis

Save This Analysis

Disease Searched: Immunodeficiency, common variable, 14 Pinned (dragged)
Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details · click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) · drag a node to pin it in place · scroll/pinch to zoom.

Member diseases (most connected first ‐ the cluster's core)

Disease ⇵ Connections in cluster ⇵ Significant partners ⇵ Curated genes ⇵
Therapy related acute myeloid leukemia and myelodysplastic syndrome 20 20 52
Neutrophilic leukemia 14 14 71
Acute myeloid leukemia, t(3;5)(q25;q34) 13 13 77
Myelodysplastic/myeloproliferative neoplasm 13 13 61
Acute leukemia of ambiguous lineage 9 9 46
Blast phase chronic myelogenous leukemia, bcr-abl1 positive 9 9 51
Therapy-related myeloid neoplasm 9 9 28
Cd4+/cd56+ hematodermic neoplasm 8 8 48
Chronic eosinophilic leukemia, not otherwise specified 8 8 61
Mast cell neoplasm 8 8 16
Systemic mastocytosis with an associated clonal hematologic non-mast cell lineage disease 8 8 27
Myeloid neoplasm 7 7 57
Myeloproliferative disease, unclassifiable 7 7 45
Essential thrombocythemia 6 6 70
Myelofibrosis 6 6 91
Myeloproliferative disorder 6 6 95
Promyelocytic leukemia 6 6 50
B-lymphoblastic leukemia/lymphoma 5 5 19
Polycythemia vera 5 5 93
Myelogenous leukemia 4 4 14
Thrombocytosis 4 4 19
Lymphoid neoplasm 3 3 65
Myelomonocytic leukemia 3 3 163
Systemic mastocytosis 3 3 36
T-lymphoblastic lymphoma 3 3 15
Testicular leydig cell tumor 3 3 21
Central nervous system anaplastic large cell lymphoma 2 2 6
Early-onset combined immunodeficiency with low ig due to dominant-negative ikaros mutation 2 2 1
Clonal hematopoiesis 1 1 56
Immunodeficiency, common variable, 14 1 1 1

Top shared genes (genes linked to 2+ member diseases ‐ top 100 shown, download for all)

Gene ⇵ Member diseases ⇵ Linked diseases
ASXL1 23 / 30 Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Cd4+/cd56+ hematodermic neoplasm and 19 more
JAK2 23 / 30 Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Cd4+/cd56+ hematodermic neoplasm and 19 more
TET2 23 / 30 Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Cd4+/cd56+ hematodermic neoplasm and 19 more
DNMT3A 22 / 30 Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), Cd4+/cd56+ hematodermic neoplasm, Central nervous system anaplastic large cell lymphoma and 18 more
IDH2 20 / 30 Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Cd4+/cd56+ hematodermic neoplasm, Central nervous system anaplastic large cell lymphoma and 16 more
TP53 20 / 30 Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), B-lymphoblastic leukemia/lymphoma, Blast phase chronic myelogenous leukemia, bcr-abl1 positive and 16 more
EZH2 19 / 30 Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), Cd4+/cd56+ hematodermic neoplasm, Chronic eosinophilic leukemia, not otherwise specified and 15 more
KIT 19 / 30 Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Cd4+/cd56+ hematodermic neoplasm and 15 more
LOC100506403 19 / 30 Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Cd4+/cd56+ hematodermic neoplasm and 15 more
NRAS 19 / 30 Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Cd4+/cd56+ hematodermic neoplasm and 15 more
FLT3 18 / 30 Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), B-lymphoblastic leukemia/lymphoma, Blast phase chronic myelogenous leukemia, bcr-abl1 positive and 14 more
NPM1 17 / 30 Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Cd4+/cd56+ hematodermic neoplasm, Central nervous system anaplastic large cell lymphoma and 13 more
SRSF2 17 / 30 Acute myeloid leukemia, t(3;5)(q25;q34), Cd4+/cd56+ hematodermic neoplasm, Chronic eosinophilic leukemia, not otherwise specified, Essential thrombocythemia and 13 more
U2AF1 17 / 30 Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Cd4+/cd56+ hematodermic neoplasm, Chronic eosinophilic leukemia, not otherwise specified and 13 more
CBL 16 / 30 Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Chronic eosinophilic leukemia, not otherwise specified and 12 more
ETV6 16 / 30 Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), B-lymphoblastic leukemia/lymphoma, Blast phase chronic myelogenous leukemia, bcr-abl1 positive and 12 more
GATA2 16 / 30 Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Chronic eosinophilic leukemia, not otherwise specified, Clonal hematopoiesis and 12 more
KRAS 16 / 30 Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), Cd4+/cd56+ hematodermic neoplasm, Essential thrombocythemia and 12 more
SF3B1 16 / 30 Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Cd4+/cd56+ hematodermic neoplasm, Chronic eosinophilic leukemia, not otherwise specified and 12 more
ABL1 15 / 30 Acute leukemia of ambiguous lineage, B-lymphoblastic leukemia/lymphoma, Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Cd4+/cd56+ hematodermic neoplasm and 11 more
IDH1 15 / 30 Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Cd4+/cd56+ hematodermic neoplasm and 11 more
NF1 15 / 30 Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Cd4+/cd56+ hematodermic neoplasm and 11 more
PTPN11 15 / 30 Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Essential thrombocythemia, Myelodysplastic/myeloproliferative neoplasm and 11 more
BCR 14 / 30 Acute leukemia of ambiguous lineage, B-lymphoblastic leukemia/lymphoma, Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Cd4+/cd56+ hematodermic neoplasm and 10 more
CUX1 14 / 30 Acute myeloid leukemia, t(3;5)(q25;q34), Chronic eosinophilic leukemia, not otherwise specified, Essential thrombocythemia, Lymphoid neoplasm and 10 more
STAG2 14 / 30 Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Chronic eosinophilic leukemia, not otherwise specified, Lymphoid neoplasm and 10 more
BCOR 13 / 30 Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Central nervous system anaplastic large cell lymphoma and 9 more
MPL 13 / 30 Acute myeloid leukemia, t(3;5)(q25;q34), Chronic eosinophilic leukemia, not otherwise specified, Essential thrombocythemia, Myelodysplastic/myeloproliferative neoplasm and 9 more
SETBP1 13 / 30 Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Chronic eosinophilic leukemia, not otherwise specified, Essential thrombocythemia and 9 more
SH2B3 13 / 30 Acute myeloid leukemia, t(3;5)(q25;q34), Cd4+/cd56+ hematodermic neoplasm, Chronic eosinophilic leukemia, not otherwise specified, Essential thrombocythemia and 9 more
CALR 12 / 30 Acute myeloid leukemia, t(3;5)(q25;q34), Cd4+/cd56+ hematodermic neoplasm, Essential thrombocythemia, Myelodysplastic/myeloproliferative neoplasm and 8 more
NOTCH1 12 / 30 Acute leukemia of ambiguous lineage, Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Cd4+/cd56+ hematodermic neoplasm, Central nervous system anaplastic large cell lymphoma and 8 more
PHF6 12 / 30 Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Essential thrombocythemia, Myelodysplastic/myeloproliferative neoplasm and 8 more
WT1 12 / 30 Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Chronic eosinophilic leukemia, not otherwise specified and 8 more
ATM 11 / 30 Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Cd4+/cd56+ hematodermic neoplasm, Chronic eosinophilic leukemia, not otherwise specified and 7 more
CEBPA 11 / 30 Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), Chronic eosinophilic leukemia, not otherwise specified, Lymphoid neoplasm and 7 more
CSF3R 11 / 30 Acute myeloid leukemia, t(3;5)(q25;q34), Chronic eosinophilic leukemia, not otherwise specified, Essential thrombocythemia, Myelodysplastic/myeloproliferative neoplasm and 7 more
IKZF1 11 / 30 Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), B-lymphoblastic leukemia/lymphoma, Blast phase chronic myelogenous leukemia, bcr-abl1 positive and 7 more
JAK3 11 / 30 Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Chronic eosinophilic leukemia, not otherwise specified and 7 more
ZRSR2 11 / 30 Acute myeloid leukemia, t(3;5)(q25;q34), Cd4+/cd56+ hematodermic neoplasm, Essential thrombocythemia, Myelodysplastic/myeloproliferative neoplasm and 7 more
BCORL1 10 / 30 Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Lymphoid neoplasm and 6 more
KMT2A 10 / 30 Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), B-lymphoblastic leukemia/lymphoma, Blast phase chronic myelogenous leukemia, bcr-abl1 positive and 6 more
PTEN 10 / 30 Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), Chronic eosinophilic leukemia, not otherwise specified, Lymphoid neoplasm and 6 more
BRAF 9 / 30 Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), Cd4+/cd56+ hematodermic neoplasm, Lymphoid neoplasm and 5 more
EP300 9 / 30 Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Essential thrombocythemia, Lymphoid neoplasm and 5 more
GNAS 9 / 30 Essential thrombocythemia, Myelodysplastic/myeloproliferative neoplasm, Myelofibrosis, Myeloid neoplasm and 5 more
RAD21 9 / 30 Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Cd4+/cd56+ hematodermic neoplasm, Lymphoid neoplasm and 5 more
RB1 9 / 30 Acute myeloid leukemia, t(3;5)(q25;q34), Cd4+/cd56+ hematodermic neoplasm, Chronic eosinophilic leukemia, not otherwise specified, Essential thrombocythemia and 5 more
ALK 8 / 30 Central nervous system anaplastic large cell lymphoma, Lymphoid neoplasm, Myelofibrosis, Myelomonocytic leukemia and 4 more
CDKN2A 8 / 30 Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), B-lymphoblastic leukemia/lymphoma, Blast phase chronic myelogenous leukemia, bcr-abl1 positive and 4 more
CSF1R 8 / 30 Acute myeloid leukemia, t(3;5)(q25;q34), Chronic eosinophilic leukemia, not otherwise specified, Essential thrombocythemia, Myelofibrosis and 4 more
KMT2C 8 / 30 Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Essential thrombocythemia, Lymphoid neoplasm and 4 more
KMT2D 8 / 30 Acute myeloid leukemia, t(3;5)(q25;q34), Lymphoid neoplasm, Myelodysplastic/myeloproliferative neoplasm, Myelofibrosis and 4 more
PDGFRB 8 / 30 Myelodysplastic/myeloproliferative neoplasm, Myelogenous leukemia, Myelomonocytic leukemia, Myeloproliferative disease, unclassifiable and 4 more
PPM1D 8 / 30 Essential thrombocythemia, Lymphoid neoplasm, Myelofibrosis, Myeloid neoplasm and 4 more
ARID1A 7 / 30 Lymphoid neoplasm, Myelodysplastic/myeloproliferative neoplasm, Myelofibrosis, Myeloid neoplasm and 3 more
ETNK1 7 / 30 Cd4+/cd56+ hematodermic neoplasm, Chronic eosinophilic leukemia, not otherwise specified, Myelodysplastic/myeloproliferative neoplasm, Myeloid neoplasm and 3 more
GATA1 7 / 30 Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Chronic eosinophilic leukemia, not otherwise specified, Myelodysplastic/myeloproliferative neoplasm and 3 more
BCL6 6 / 30 Myelodysplastic/myeloproliferative neoplasm, Myeloid neoplasm, Myelomonocytic leukemia, Myeloproliferative disease, unclassifiable and 2 more
CBLB 6 / 30 Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Cd4+/cd56+ hematodermic neoplasm, Myeloid neoplasm, Myelomonocytic leukemia and 2 more
CREBBP 6 / 30 Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Myelodysplastic/myeloproliferative neoplasm, Myeloid neoplasm, Myelomonocytic leukemia and 2 more
FAT4 6 / 30 Chronic eosinophilic leukemia, not otherwise specified, Essential thrombocythemia, Myelofibrosis, Myelomonocytic leukemia and 2 more
KDM6A 6 / 30 Acute myeloid leukemia, t(3;5)(q25;q34), Cd4+/cd56+ hematodermic neoplasm, Myelomonocytic leukemia, Myeloproliferative disease, unclassifiable and 2 more
STAT5B 6 / 30 Chronic eosinophilic leukemia, not otherwise specified, Myelodysplastic/myeloproliferative neoplasm, Myelomonocytic leukemia, Myeloproliferative disease, unclassifiable and 2 more
ATRX 5 / 30 Cd4+/cd56+ hematodermic neoplasm, Chronic eosinophilic leukemia, not otherwise specified, Myelodysplastic/myeloproliferative neoplasm, Myelofibrosis and 1 more
CHEK2 5 / 30 Clonal hematopoiesis, Essential thrombocythemia, Myelofibrosis, Myeloproliferative disorder and 1 more
FBXO11 5 / 30 Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Lymphoid neoplasm, Myeloid neoplasm and 1 more
FBXW7 5 / 30 Chronic eosinophilic leukemia, not otherwise specified, Lymphoid neoplasm, Myelodysplastic/myeloproliferative neoplasm, Myeloid neoplasm and 1 more
GATA3 5 / 30 B-lymphoblastic leukemia/lymphoma, Myeloid neoplasm, Myeloproliferative disease, unclassifiable, Neutrophilic leukemia and 1 more
PCM1 5 / 30 Acute leukemia of ambiguous lineage, Chronic eosinophilic leukemia, not otherwise specified, Myelodysplastic/myeloproliferative neoplasm, Neutrophilic leukemia and 1 more
PDGFRA 5 / 30 Acute myeloid leukemia, t(3;5)(q25;q34), B-lymphoblastic leukemia/lymphoma, Chronic eosinophilic leukemia, not otherwise specified, Myelodysplastic/myeloproliferative neoplasm and 1 more
PTCH1 5 / 30 Lymphoid neoplasm, Myelofibrosis, Myelomonocytic leukemia, Testicular leydig cell tumor and 1 more
TCF3 5 / 30 Acute leukemia of ambiguous lineage, B-lymphoblastic leukemia/lymphoma, Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Myeloid neoplasm and 1 more
CARD11 4 / 30 Acute myeloid leukemia, t(3;5)(q25;q34), Lymphoid neoplasm, Myeloid neoplasm, Neutrophilic leukemia
EWSR1 4 / 30 Acute leukemia of ambiguous lineage, Lymphoid neoplasm, Myelofibrosis, Therapy related acute myeloid leukemia and myelodysplastic syndrome
HRAS 4 / 30 Acute myeloid leukemia, t(3;5)(q25;q34), Cd4+/cd56+ hematodermic neoplasm, Lymphoid neoplasm, Myelomonocytic leukemia
JAK1 4 / 30 Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), Myelomonocytic leukemia, Myeloproliferative disease, unclassifiable
MET 4 / 30 Acute myeloid leukemia, t(3;5)(q25;q34), Cd4+/cd56+ hematodermic neoplasm, Myelomonocytic leukemia, Polycythemia vera
MUC16 4 / 30 Essential thrombocythemia, Myelofibrosis, Polycythemia vera, Therapy-related myeloid neoplasm
NTRK2 4 / 30 Myelofibrosis, Myeloid neoplasm, Neutrophilic leukemia, Polycythemia vera
NUP214 4 / 30 Acute leukemia of ambiguous lineage, Myelomonocytic leukemia, Myeloproliferative disorder, T-lymphoblastic lymphoma
PRDM1 4 / 30 Essential thrombocythemia, Myeloid neoplasm, Neutrophilic leukemia, Polycythemia vera
SMC1A 4 / 30 Acute myeloid leukemia, t(3;5)(q25;q34), Myelomonocytic leukemia, Myeloproliferative disease, unclassifiable, Neutrophilic leukemia
SUZ12 4 / 30 Myelofibrosis, Myelomonocytic leukemia, Polycythemia vera, Therapy related acute myeloid leukemia and myelodysplastic syndrome
APC 3 / 30 Cd4+/cd56+ hematodermic neoplasm, Myelofibrosis, Polycythemia vera
ASXL2 3 / 30 Myelodysplastic/myeloproliferative neoplasm, Myeloid neoplasm, Neutrophilic leukemia
CBFA2T3 3 / 30 Essential thrombocythemia, Myelomonocytic leukemia, Myeloproliferative disorder
CCND3 3 / 30 Acute leukemia of ambiguous lineage, Myeloid neoplasm, Systemic mastocytosis
CDKN1B 3 / 30 Acute myeloid leukemia, t(3;5)(q25;q34), Myelodysplastic/myeloproliferative neoplasm, Myelomonocytic leukemia
CHD4 3 / 30 Essential thrombocythemia, Polycythemia vera, Thrombocytosis
CTCF 3 / 30 Acute myeloid leukemia, t(3;5)(q25;q34), Myelomonocytic leukemia, Myeloproliferative disorder
DICER1 3 / 30 Essential thrombocythemia, Lymphoid neoplasm, Myelofibrosis
EML4 3 / 30 Acute myeloid leukemia, t(3;5)(q25;q34), Lymphoid neoplasm, Polycythemia vera
EPHA7 3 / 30 Essential thrombocythemia, Mast cell neoplasm, Myelofibrosis
ERBB4 3 / 30 Essential thrombocythemia, Myelomonocytic leukemia, Systemic mastocytosis
FAT1 3 / 30 Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Myelofibrosis, Polycythemia vera
HLA-A 3 / 30 Myelodysplastic/myeloproliferative neoplasm, Myeloid neoplasm, Neutrophilic leukemia
IKZF3 3 / 30 Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Cd4+/cd56+ hematodermic neoplasm, Lymphoid neoplasm
MALT1 3 / 30 Myeloid neoplasm, Myeloproliferative disease, unclassifiable, Neutrophilic leukemia
MED12 3 / 30 Acute myeloid leukemia, t(3;5)(q25;q34), Chronic eosinophilic leukemia, not otherwise specified, Myeloproliferative disease, unclassifiable
What do these columns mean?
Connections in cluster
How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
Significant partners
How many of those links are statistically significant (FDR q < 0.05).
Curated genes
Distinct curated genes linked to that disease in GeDiPNet.
Member diseases (Top shared genes)
How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
Overlap genes (x / y)
x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
Cluster gene count
Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
Fold enrichment
Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
P-value / FDR q-value
Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
Shared genes (Pairs within this cluster)
Number of curated genes the two diseases in that row have in common.
Similarity score (Pairs within this cluster)
Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.

Enriched Pathways (why this cluster is grouped, biologically)

Pathway ⇵ Source ⇵ Overlap genes ⇵ Fold enrichment ⇵ P-value ⇵ FDR q-value ⇵
Pathways in cancer
PDGFRA, ABL1, BCR, CDKN2A, FLT3, TP53, PDGFRB, CSF3R, JAK2, RUNX1, TERT, CBL
 KEGG 106 / 533 4.9× 1.65e-45 1.76e-41 ✓ sig.
Transcriptional misregulation in cancer
PBX1, TCF3, ETV6, PAX5, FLT3, TP53, KMT2A, ATM, MEIS1, RUNX1, CEBPA, CEBPE
 KEGG 48 / 198 6.0× 1.56e-24 2.32e-21 ✓ sig.
Prostate cancer
PDGFRA, TP53, PDGFRB, KRAS, NRAS, AKT1, BCL2, FOXO1, FGFR1, IGF1R, PDGFA, PDGFB
 KEGG 34 / 98 8.6× 3.23e-23 4.13e-20 ✓ sig.
EGFR tyrosine kinase inhibitor resistance
PDGFRA, PDGFRB, JAK2, KRAS, NF1, NRAS, AKT1, BCL2, BCL2L1, IGF1R, FGF2, PDGFA
 KEGG 31 / 80 9.6× 5.88e-23 7.37e-20 ✓ sig.
Acute myeloid leukemia
FLT3, RUNX1, KRAS, NRAS, AKT1, CEBPA, CEBPE, ITGAM, KIT, PML, RARA, ZBTB16
 KEGG 27 / 68 9.8× 1.77e-20 1.42e-17 ✓ sig.
Chronic myeloid leukemia
ABL1, BCR, CDKN2A, TP53, RUNX1, CBL, KRAS, NRAS, PTPN11, AKT1, BCL2L1, MECOM
 KEGG 28 / 77 9.0× 5.76e-20 4.26e-17 ✓ sig.
Central carbon metabolism in cancer
PDGFRA, FLT3, TP53, PDGFRB, KRAS, NRAS, AKT1, IDH1, IDH2, KIT, FGFR1, HRAS
 KEGG 27 / 71 9.4× 6.81e-20 5.01e-17 ✓ sig.
Endometrial cancer
TP53, KRAS, NRAS, AKT1, BRAF, HRAS, PIK3R2, CTNNA1, SOS1, PTEN, FOXO3, APC
 KEGG 25 / 59 10.5× 6.92e-20 5.06e-17 ✓ sig.
PI3K-Akt signaling pathway
PDGFRA, FLT3, TP53, PDGFRB, CSF3R, JAK2, TCL1A, KRAS, NRAS, AKT1, KIT, BCL2
 KEGG 57 / 361 3.9× 3.36e-19 2.21e-16 ✓ sig.
Melanoma
PDGFRA, CDKN2A, TP53, PDGFRB, KRAS, NRAS, AKT1, FGFR1, IGF1R, FGF2, PDGFA, PDGFB
 KEGG 26 / 73 8.8× 2.31e-18 1.31e-15 ✓ sig.
Proteoglycans in cancer
TP53, ITPR2, CBL, KRAS, NRAS, PTPN11, RRAS, AKT1, CD44, ROCK1, SMO, FGFR1
 KEGG 41 / 204 5.0× 6.81e-18 3.57e-15 ✓ sig.
Colorectal cancer
TP53, KRAS, NRAS, AKT1, BIRC5, BCL2, TGFB1, BRAF, HRAS, PIK3R2, MSH2, SOS1
 KEGG 27 / 87 7.7× 2.95e-17 1.39e-14 ✓ sig.
Non-small cell lung cancer
CDKN2A, TP53, KRAS, NRAS, AKT1, BRAF, HRAS, JAK3, PIK3R2, STAT5B, RB1, SOS1
 KEGG 25 / 73 8.5× 3.13e-17 1.46e-14 ✓ sig.
JAK-STAT signaling pathway
PDGFRA, PDGFRB, CSF3R, IL20RB, JAK2, MPL, THPO, PTPN11, AKT1, IFNG, LEP, BCL2
 KEGG 36 / 168 5.3× 8.74e-17 3.68e-14 ✓ sig.
MicroRNAs in cancer
FOXP1, PDGFRA, ABL1, CDKN2A, TP53, PDGFRB, ATM, KRAS, NRAS, CD44, DNMT3A, ROCK1
 KEGG 48 / 311 3.8× 6.72e-16 2.41e-13 ✓ sig.

Enriched GO Terms (Biological Process, a second line of biological evidence)

GO term ⇵ GO ID ⇵ Overlap genes ⇵ Fold enrichment ⇵ P-value ⇵ FDR q-value ⇵
positive regulation of transcription by RNA polymerase II
GATA3, PBX1, TCF3, ETV6, HLF, AUTS2, PAX5, ABL1, CDKN2A, TP53, KMT2A, ASXL1
 GO:0045944 119 / 1,208 3.8× 2.97e-38 3.23e-34 ✓ sig.
positive regulation of DNA-templated transcription
GATA3, TCF3, CDKN2A, TP53, KMT2A, CHEK2, ELF1, GATA2, NPAT, PARP1, RUNX1, ZFHX3
 GO:0045893 85 / 778 4.2× 3.89e-30 2.35e-26 ✓ sig.
negative regulation of transcription by RNA polymerase II
GATA3, FOXP1, TCF3, ETV6, PAX5, CDKN2A, TP53, GATA2, NRIP1, PARP1, PURB, RUNX1
 GO:0000122 89 / 1,002 3.4× 5.63e-25 1.74e-21 ✓ sig.
positive regulation of gene expression
GATA3, CDKN2A, TP53, KMT2A, ATM, GATA2, RLN2, CALR, KRAS, AKT1, CEBPA, CEBPE
 GO:0010628 59 / 504 4.5× 1.78e-22 4.01e-19 ✓ sig.
positive regulation of cell population proliferation
PDGFRA, FLT3, PDGFRB, CSF3R, BTC, JAK2, MEIS1, CALR, THPO, BIRC5, GLI1, IFNG
 GO:0008284 58 / 532 4.2× 1.42e-20 2.46e-17 ✓ sig.
cell population proliferation
GATA3, PBX1, TP53, BTC, IFT80, THPO, KRAS, NF1, AKT1, CEBPA, KIT, SMO
 GO:0008283 41 / 263 6.0× 1.84e-20 3.13e-17 ✓ sig.
negative regulation of DNA-templated transcription
GATA3, FOXP1, CDKN2A, IKZF1, TP53, SRSF2, NPAT, PARP1, PURB, THRB, ZNF318, CALR
 GO:0045892 63 / 631 3.8× 2.70e-20 4.53e-17 ✓ sig.
regulation of cell population proliferation
PBX1, ABL1, TP53, NF1, CEBPA, KIT, NPM1, FOXO1, TGFB1, BRAF, HRAS, NOTCH1
 GO:0042127 35 / 201 6.7× 3.23e-19 4.61e-16 ✓ sig.
regulation of gene expression
FOXP1, ABL1, CDKN2A, KMT2A, ATM, SLC8A1, TET2, NF1, DNMT3A, GLI1, GLI2, ROCK1
 GO:0010468 47 / 402 4.5× 4.82e-18 5.79e-15 ✓ sig.
apoptotic process
ABL1, CDKN2A, TP53, KMT2A, BTC, CHEK2, IFT80, JAK2, PARP1, PPIA, NF1, AKT1
 GO:0006915 63 / 747 3.2× 1.26e-16 1.21e-13 ✓ sig.
chromatin remodeling
GATA3, ATM, JAK2, NPM1, PML, MECOM, ATRX, EP300, BCOR, ATR, KMT2C, PRDM2
 GO:0006338 40 / 320 4.8× 1.62e-16 1.52e-13 ✓ sig.
regulation of transcription by RNA polymerase II
GATA3, FOXP1, TCF3, ETV6, HLF, PAX5, IKZF1, TP53, ELF1, GATA2, NRIP1, PURB
 GO:0006357 98 / 1,602 2.4× 6.42e-16 5.42e-13 ✓ sig.
positive regulation of miRNA transcription
GATA3, TP53, GATA2, TERT, PPARG, WT1, MYB, FGF2, PDGFB, TGFB1, AR, FOXO3
 GO:1902895 18 / 56 12.4× 1.85e-15 1.46e-12 ✓ sig.
DNA damage response
FOXP1, ABL1, TP53, ATM, CHEK2, PARP1, RTEL1, STXBP4, CBL, BCL2, FOXO1, MSH5
 GO:0006974 52 / 577 3.5× 5.03e-15 3.64e-12 ✓ sig.
regulation of DNA-templated transcription
GATA3, FOXP1, PBX1, TCF3, ETV6, HLF, PAX5, ABL1, TP53, KMT2A, ASXL1, CHEK2
 GO:0006355 90 / 1,454 2.4× 6.42e-15 4.55e-12 ✓ sig.

Pairs within this cluster, by significance

Disease A ⇵ Disease B ⇵ Similarity score ⇵ Shared genes ⇵ P-value ⇵ FDR q-value ⇵
Acute myeloid leukemia, t(3;5)(q25;q34) Myelomonocytic leukemia 0.335 59 5.71e-108 2.56e-106 ✓ sig.
Myeloid neoplasm Neutrophilic leukemia 0.557 44 4.37e-102 1.86e-100 ✓ sig.
Myelodysplastic/myeloproliferative neoplasm Neutrophilic leukemia 0.471 41 2.45e-89 9.23e-88 ✓ sig.
Myelomonocytic leukemia Therapy related acute myeloid leukemia and myelodysplastic syndrome 0.271 45 9.90e-87 3.67e-85 ✓ sig.
Acute myeloid leukemia, t(3;5)(q25;q34) Therapy related acute myeloid leukemia and myelodysplastic syndrome 0.453 39 4.76e-86 1.76e-84 ✓ sig.
Acute myeloid leukemia, t(3;5)(q25;q34) Neutrophilic leukemia 0.416 42 5.78e-86 2.13e-84 ✓ sig.
Myelomonocytic leukemia Neutrophilic leukemia 0.272 49 4.14e-85 1.52e-83 ✓ sig.
Myelodysplastic/myeloproliferative neoplasm Therapy related acute myeloid leukemia and myelodysplastic syndrome 0.507 37 4.19e-85 1.54e-83 ✓ sig.
Myelofibrosis Polycythemia vera 0.343 46 4.79e-84 1.75e-82 ✓ sig.
Acute myeloid leukemia, t(3;5)(q25;q34) Chronic eosinophilic leukemia, not otherwise specified 0.421 40 1.19e-83 4.33e-82 ✓ sig.
Acute myeloid leukemia, t(3;5)(q25;q34) Myelodysplastic/myeloproliferative neoplasm 0.411 39 3.49e-81 1.24e-79 ✓ sig.
Myelofibrosis Therapy related acute myeloid leukemia and myelodysplastic syndrome 0.373 38 7.84e-79 2.75e-77 ✓ sig.
Neutrophilic leukemia Therapy related acute myeloid leukemia and myelodysplastic syndrome 0.434 36 1.29e-78 4.53e-77 ✓ sig.
Essential thrombocythemia Myelofibrosis 0.339 40 6.56e-76 2.26e-74 ✓ sig.
Myeloproliferative disease, unclassifiable Neutrophilic leukemia 0.430 34 7.34e-76 2.52e-74 ✓ sig.
Chronic eosinophilic leukemia, not otherwise specified Myelodysplastic/myeloproliferative neoplasm 0.412 35 2.60e-74 8.83e-73 ✓ sig.
Chronic eosinophilic leukemia, not otherwise specified Neutrophilic leukemia 0.387 36 4.88e-74 1.65e-72 ✓ sig.
Myelodysplastic/myeloproliferative neoplasm Myeloid neoplasm 0.425 34 1.00e-73 3.38e-72 ✓ sig.
Essential thrombocythemia Polycythemia vera 0.325 39 4.90e-73 1.65e-71 ✓ sig.
Myeloproliferative disorder Therapy related acute myeloid leukemia and myelodysplastic syndrome 0.333 36 3.83e-72 1.28e-70 ✓ sig.
Myelofibrosis Neutrophilic leukemia 0.317 38 1.09e-70 3.59e-69 ✓ sig.
Blast phase chronic myelogenous leukemia, bcr-abl1 positive Neutrophilic leukemia 0.388 33 4.31e-70 1.42e-68 ✓ sig.
Acute myeloid leukemia, t(3;5)(q25;q34) Blast phase chronic myelogenous leukemia, bcr-abl1 positive 0.363 33 1.77e-68 5.74e-67 ✓ sig.
Neutrophilic leukemia Polycythemia vera 0.303 37 6.69e-68 2.16e-66 ✓ sig.
Myelodysplastic/myeloproliferative neoplasm Myelofibrosis 0.307 35 3.32e-66 1.06e-64 ✓ sig.
Chronic eosinophilic leukemia, not otherwise specified Therapy related acute myeloid leukemia and myelodysplastic syndrome 0.388 31 3.67e-66 1.17e-64 ✓ sig.
Myelofibrosis Myeloproliferative disorder 0.262 38 9.79e-64 3.05e-62 ✓ sig.
Acute myeloid leukemia, t(3;5)(q25;q34) Myeloproliferative disorder 0.273 36 6.37e-63 1.96e-61 ✓ sig.
Myeloproliferative disorder Neutrophilic leukemia 0.276 35 2.81e-62 8.60e-61 ✓ sig.
Acute myeloid leukemia, t(3;5)(q25;q34) Myeloproliferative disease, unclassifiable 0.337 30 2.83e-62 8.65e-61 ✓ sig.
Acute myeloid leukemia, t(3;5)(q25;q34) Cd4+/cd56+ hematodermic neoplasm 0.333 30 8.45e-62 2.58e-60 ✓ sig.
Essential thrombocythemia Neutrophilic leukemia 0.305 32 1.34e-60 4.03e-59 ✓ sig.
Acute myeloid leukemia, t(3;5)(q25;q34) Myeloid neoplasm 0.303 30 3.35e-58 9.88e-57 ✓ sig.
Blast phase chronic myelogenous leukemia, bcr-abl1 positive Chronic eosinophilic leukemia, not otherwise specified 0.341 28 5.81e-58 1.71e-56 ✓ sig.
Myelodysplastic/myeloproliferative neoplasm Myeloproliferative disorder 0.264 32 8.54e-58 2.50e-56 ✓ sig.
Cd4+/cd56+ hematodermic neoplasm Neutrophilic leukemia 0.326 28 1.58e-57 4.60e-56 ✓ sig.
Myelodysplastic/myeloproliferative neoplasm Myeloproliferative disease, unclassifiable 0.351 27 2.65e-57 7.70e-56 ✓ sig.
Acute myeloid leukemia, t(3;5)(q25;q34) Essential thrombocythemia 0.277 31 1.44e-56 4.16e-55 ✓ sig.
Myeloid neoplasm Myeloproliferative disease, unclassifiable 0.356 26 8.86e-56 2.54e-54 ✓ sig.
Blast phase chronic myelogenous leukemia, bcr-abl1 positive Therapy related acute myeloid leukemia and myelodysplastic syndrome 0.351 26 3.24e-55 9.22e-54 ✓ sig.
Blast phase chronic myelogenous leukemia, bcr-abl1 positive Polycythemia vera 0.261 29 2.43e-54 6.85e-53 ✓ sig.
Myeloproliferative disease, unclassifiable Therapy related acute myeloid leukemia and myelodysplastic syndrome 0.357 25 4.86e-54 1.36e-52 ✓ sig.
Blast phase chronic myelogenous leukemia, bcr-abl1 positive Cd4+/cd56+ hematodermic neoplasm 0.357 25 5.47e-54 1.53e-52 ✓ sig.
Cd4+/cd56+ hematodermic neoplasm Chronic eosinophilic leukemia, not otherwise specified 0.325 26 7.74e-54 2.17e-52 ✓ sig.
Myeloid neoplasm Polycythemia vera 0.250 29 1.42e-52 3.93e-51 ✓ sig.
Myeloid neoplasm Therapy related acute myeloid leukemia and myelodysplastic syndrome 0.313 25 5.72e-51 1.56e-49 ✓ sig.
Cd4+/cd56+ hematodermic neoplasm Therapy related acute myeloid leukemia and myelodysplastic syndrome 0.333 24 7.71e-51 2.09e-49 ✓ sig.
Acute leukemia of ambiguous lineage Chronic eosinophilic leukemia, not otherwise specified 0.304 24 2.13e-49 5.70e-48 ✓ sig.
Acute leukemia of ambiguous lineage Acute myeloid leukemia, t(3;5)(q25;q34) 0.272 25 2.38e-49 6.37e-48 ✓ sig.
Acute leukemia of ambiguous lineage Blast phase chronic myelogenous leukemia, bcr-abl1 positive 0.333 23 2.83e-49 7.55e-48 ✓ sig.
Myelodysplastic/myeloproliferative neoplasm Therapy-related myeloid neoplasm 0.328 21 3.45e-49 9.17e-48 ✓ sig.
Acute myeloid leukemia, t(3;5)(q25;q34) Lymphoid neoplasm 0.245 27 2.45e-48 6.43e-47 ✓ sig.
Essential thrombocythemia Therapy related acute myeloid leukemia and myelodysplastic syndrome 0.266 25 8.80e-48 2.30e-46 ✓ sig.
Therapy related acute myeloid leukemia and myelodysplastic syndrome Therapy-related myeloid neoplasm 0.357 20 9.69e-48 2.52e-46 ✓ sig.
Myelodysplastic/myeloproliferative neoplasm Systemic mastocytosis with an associated clonal hematologic non-mast cell lineage disease 0.303 20 2.48e-45 6.26e-44 ✓ sig.
Acute leukemia of ambiguous lineage Therapy related acute myeloid leukemia and myelodysplastic syndrome 0.292 21 1.85e-43 4.55e-42 ✓ sig.
Systemic mastocytosis with an associated clonal hematologic non-mast cell lineage disease Therapy related acute myeloid leukemia and myelodysplastic syndrome 0.305 18 6.83e-41 1.62e-39 ✓ sig.
Myeloid neoplasm Therapy-related myeloid neoplasm 0.290 18 1.13e-40 2.67e-39 ✓ sig.
Lymphoid neoplasm Neutrophilic leukemia 0.213 23 4.81e-40 1.13e-38 ✓ sig.
Lymphoid neoplasm Therapy related acute myeloid leukemia and myelodysplastic syndrome 0.228 21 6.11e-39 1.41e-37 ✓ sig.
Acute leukemia of ambiguous lineage Cd4+/cd56+ hematodermic neoplasm 0.257 18 1.43e-36 3.20e-35 ✓ sig.
Myeloproliferative disease, unclassifiable Systemic mastocytosis with an associated clonal hematologic non-mast cell lineage disease 0.268 15 3.24e-33 6.83e-32 ✓ sig.
Therapy related acute myeloid leukemia and myelodysplastic syndrome Thrombocytosis 0.255 14 5.46e-33 1.15e-31 ✓ sig.
Mast cell neoplasm Systemic mastocytosis with an associated clonal hematologic non-mast cell lineage disease 0.387 12 4.42e-32 9.09e-31 ✓ sig.
Myelodysplastic/myeloproliferative neoplasm Thrombocytosis 0.219 14 7.72e-32 1.57e-30 ✓ sig.
Systemic mastocytosis with an associated clonal hematologic non-mast cell lineage disease Therapy-related myeloid neoplasm 0.333 13 1.14e-31 2.31e-30 ✓ sig.
Cd4+/cd56+ hematodermic neoplasm Mast cell neoplasm 0.240 12 1.31e-28 2.49e-27 ✓ sig.
Mast cell neoplasm Therapy related acute myeloid leukemia and myelodysplastic syndrome 0.218 12 5.53e-28 1.04e-26 ✓ sig.
Chronic eosinophilic leukemia, not otherwise specified Mast cell neoplasm 0.185 12 6.36e-27 1.16e-25 ✓ sig.
Mast cell neoplasm Therapy-related myeloid neoplasm 0.313 10 1.19e-25 2.07e-24 ✓ sig.
Myelogenous leukemia Myeloproliferative disease, unclassifiable 0.208 10 3.23e-24 5.39e-23 ✓ sig.
Promyelocytic leukemia Therapy-related myeloid neoplasm 0.169 11 5.25e-22 8.17e-21 ✓ sig.
Acute leukemia of ambiguous lineage T-lymphoblastic lymphoma 0.184 9 1.56e-20 2.33e-19 ✓ sig.
Myelodysplastic/myeloproliferative neoplasm Testicular leydig cell tumor 0.143 10 5.17e-20 7.57e-19 ✓ sig.
Acute leukemia of ambiguous lineage B-lymphoblastic leukemia/lymphoma 0.173 9 1.51e-19 2.17e-18 ✓ sig.
Essential thrombocythemia Testicular leydig cell tumor 0.127 10 2.38e-19 3.40e-18 ✓ sig.
Therapy-related myeloid neoplasm Thrombocytosis 0.222 8 5.72e-19 8.09e-18 ✓ sig.
B-lymphoblastic leukemia/lymphoma Blast phase chronic myelogenous leukemia, bcr-abl1 positive 0.153 9 6.94e-19 9.79e-18 ✓ sig.
Systemic mastocytosis with an associated clonal hematologic non-mast cell lineage disease Thrombocytosis 0.216 8 8.25e-19 1.16e-17 ✓ sig.
Acute leukemia of ambiguous lineage Myelogenous leukemia 0.167 8 1.84e-18 2.55e-17 ✓ sig.
Testicular leydig cell tumor Therapy related acute myeloid leukemia and myelodysplastic syndrome 0.145 9 2.91e-18 4.01e-17 ✓ sig.
Promyelocytic leukemia Therapy related acute myeloid leukemia and myelodysplastic syndrome 0.122 11 4.15e-18 5.69e-17 ✓ sig.
Clonal hematopoiesis Myeloproliferative disorder 0.095 13 8.46e-18 1.14e-16 ✓ sig.
Myelodysplastic/myeloproliferative neoplasm Promyelocytic leukemia 0.111 11 3.05e-17 4.04e-16 ✓ sig.
Acute leukemia of ambiguous lineage Promyelocytic leukemia 0.120 10 6.42e-17 8.40e-16 ✓ sig.
Blast phase chronic myelogenous leukemia, bcr-abl1 positive Promyelocytic leukemia 0.111 10 3.53e-16 4.48e-15 ✓ sig.
B-lymphoblastic leukemia/lymphoma Cd4+/cd56+ hematodermic neoplasm 0.123 7 3.33e-14 3.88e-13 ✓ sig.
Myelogenous leukemia Systemic mastocytosis with an associated clonal hematologic non-mast cell lineage disease 0.143 5 1.13e-11 1.14e-10 ✓ sig.
Systemic mastocytosis Therapy-related myeloid neoplasm 0.107 6 1.75e-11 1.73e-10 ✓ sig.
T-lymphoblastic lymphoma Therapy-related myeloid neoplasm 0.139 5 2.13e-11 2.10e-10 ✓ sig.
Systemic mastocytosis Systemic mastocytosis with an associated clonal hematologic non-mast cell lineage disease 0.105 6 2.26e-11 2.23e-10 ✓ sig.
Mast cell neoplasm Systemic mastocytosis 0.104 5 2.18e-10 1.99e-9 ✓ sig.
B-lymphoblastic leukemia/lymphoma Myelogenous leukemia 0.143 4 9.07e-10 7.86e-9 ✓ sig.
Central nervous system anaplastic large cell lymphoma T-lymphoblastic lymphoma 0.158 3 1.47e-8 1.14e-7 ✓ sig.
Central nervous system anaplastic large cell lymphoma Mast cell neoplasm 0.150 3 1.81e-8 1.40e-7 ✓ sig.
Early-onset combined immunodeficiency with low ig due to dominant-negative ikaros mutation Mast cell neoplasm 0.059 1 1.03e-3 1.57e-3 ✓ sig.
B-lymphoblastic leukemia/lymphoma Early-onset combined immunodeficiency with low ig due to dominant-negative ikaros mutation 0.053 1 1.16e-3 1.73e-3 ✓ sig.
Immunodeficiency, common variable, 14 Promyelocytic leukemia 0.020 1 3.23e-3 4.07e-3 ✓ sig.